Roche drug shows major success with reducing bleeding in hemophilia patients

May 21, 2018

Recently released results from two clinical trials showed that a Roche drug can dramatically reduce bleeding in hemophilia patients.  

According to the company, patients who had hemophilia A but no preventative treatments experienced a 96 percent reduction in bleeding when taking Hemlibra. Patients who had taken clotting factors as a preventative measure also saw a 68 percent reduction in bleeding.

Hemlibra has already been approved for patients with inhibitors — or, antibodies that create a resistance to replacement clotting factors. The company said it hopes that the results from these new studies will help make Hemlibra the go-to for treating hemophilia A, and that the sales potential could reach $5 billion.

However, the company’s supremacy on the market could be challenged by several companies working on developing hemophilia gene therapy treatments, which, if successful, could offer a one-shot cure.

Read the full Reuters report.  

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments